Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

By sjmartinez • April 7, 2023

Kusuma FK, Prabhu A, Tieo G, Ahmed SM, Dakle P, Yong WK, Pathak E, Madan V, Jiang YY, Tam WL, Kappei D, Dröge P, Koeffler HP, Jeitany M. Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT). Nat Commun. 2023 Apr 6;14(1):1919. doi: 10.1038/s41467-023-37633-3. PMID: 37024489.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer

Zhang L, Teng PC, Cavassani KA, Wang J, Grasso C, Watson J, Chen Z, Tu KH, Salumbides B, Rohena-Rivera K, Gevorkian L, Kim M, You[...]

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Nielsen W, Kharouf F, Grajales CM, Thayaparan A, Anderson M, Strand V, Simon L, Bonilla D, Morand E, Thumboo J, Aringer M, Mosca M, Bruce[...]

Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk

Choi SH, Jurgens SJ, Xiao L, Hill MC, Haggerty CM, Sveinbjörnsson G, Morrill VN, Marston NA, Weng LC, Pirruccello JP, Arnar DO, Gudbjartsson DF, Mantineo[...]